Fintel reports that on November 13, 2024, JMP Securities downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) ...

Fintel reports that on November 13, 2024, TD Cowen downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) from ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Syros Pharmaceuticals (NASDAQ: NASDAQ:SYRS) provided a comprehensive update on its progress with tamibarotene, a potential treatment for higher-risk myelodysplastic syndromes (MDS) with RARA gene ...

Syros Pharmaceuticals (NASDAQ: NASDAQ:SYRS) provided a comprehensive update on its progress with tamibarotene, a potential treatment for higher-risk myelodysplastic syndromes (MDS) with RARA gene ...

Cash and Cash Equivalents: $58.3 million as of September 30, 2024, compared to $79 million as of June 30, 2024. Syros Pharmaceuticals Inc (NASDAQ:SYRS) is advancing tamibarotene as a potential new ...

Syros Pharmaceuticals Inc (NASDAQ:SYRS) is advancing tamibarotene as a potential new standard of care for higher-risk MDS patients with RARA overexpression, targeting a significant unmet medical need.

Syros Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.16, expectations were $-0.72. Operator: Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 ...

Syros Pharmaceuticals ( (SYRS)) has released its Q3 earnings. Here is a breakdown of the information Syros Pharmaceuticals presented to its investors. Syros Pharmaceuticals, Inc., a ...